This study, called SUNFLOWER, is looking at how well a medication called anifrolumab works for people with Systemic Lupus Erythematosus (SLE), an autoimmune disease. You might be able to join if you are between 18 and 70 years old, have a confirmed SLE diagnosis, and have certain positive blood tests (ANA, anti-dsDNA, anti-Smith). You also need to be currently taking antimalarial medications, with or without steroids (OCS). The study will give anifrolumab as an injection under the skin once a week. Researchers want to see if anifrolumab can help you achieve "DORIS remission," which is a way to measure if your lupus symptoms are well-controlled, after 52 weeks. This study is for people who haven't used certain strong immunosuppressant or biologic medications before.

Study design

This interventional study plans to enroll approximately 245 participants. It is not specified if it is randomized or blinded.

What's involved

You would participate in the study for about 69 weeks, including a screening period of up to 35 days and a 52-week treatment period where you receive anifrolumab injections weekly.

Compensation

Not stated in the trial record.

Follow-up

After the 52-week treatment period, if you stop taking anifrolumab, there will be an additional safety follow-up for 12 weeks after your last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.